Evidence map›Paper›PMID 36034781›Full record

ReviewFrontiers in pharmacology2022

TMAO as a potential biomarker and therapeutic target for chronic kidney disease: A review.

Ye Zixin, Chen Lulu, Zeng Xiangchang, Fang Qing, Zheng Binjie, Luo Chunyang, Rao Tai, Ouyang Dongsheng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. The gut as a central hub for multi-organ crosstalk in aging.Cellular and molecular life sciences : CMLS · 2026
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ye ZixinDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Chen LuluHunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha, China.
Zeng XiangchangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Fang QingHunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha, China.
Zheng BinjieDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Luo ChunyangDepartment of Clinical Pharmacy, Affiliated Hospital of Xiangnan University, Chenzhou, China.
Rao TaiDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Ouyang DongshengDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gut microbiota and its metabolites have become a hotspot of recent research. Trimethylamine N-oxide (TMAO) metabolized by the gut microbiota is closely related to many diseases such as cardiovascular disease, chronic kidney disease, type 2 diabetes, etc. Chronic kidney disease (CKD) is an important contributor to morbidity and mortality from non-communicable diseases. Recently, increasing focus has been put on the role of TMAO in the development and progress of chronic kidney disease. The level of TMAO in patients with chronic kidney disease is significantly increased, and a high level of TMAO deteriorates chronic kidney disease. This article describes the relationship between TMAO and chronic kidney disease and the research progress of drugs targeted TMAO, providing a reference for the development of anti-chronic kidney disease drugs targeted TMAO.

Indexed as

chronic kidney diseasegut microbiotamechanismtargeted TMAO drugstreatmenttrimethylamine N-oxide

Identifiers

PMID36034781
PMCPMC9411716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.